Séan Mc Cafferty

TL;DR: It is found that mRNAs containing the N(1)-methylpseudouridine (m1Ψ) modification alone and/or in combination with 5-methylcytidine ( m5C) outperformed the current state-of-the-art pseudouridine-based mRNA platform and may serve as a new standard in the field of modified mRNA-based therapeutics.

TL;DR: The different synthetic mRNA platforms, their production and purification, strategies to tackle the inherent innate immunogenicity of synthetic mRNA, the recent progress in the development of nanoformulations for the in vivo delivery of mRNA, as well as the efficacy and safety of mRNA therapeutics in recent clinical trials are described.

TL;DR: It is assumed that the efficacy of sr-mRNA vaccines after intradermal electroporation might be increased by strategies that temper their inherent innate immunogenicity.

TL;DR: The significant down-regulation of several tested DNA damage response (DDR) genes, after increasing miR-30c or reducing CDK12 expression, suggests a possible role for miR -30c in regulating embryo development through DDR pathways.

TL;DR: Interestingly, the self-replicating mRNA was able to maintain its high expression levels during at least 12 days during intradermal electroporation, while the expression of pDNA and the nonreplicating mRNAs dropped after respectively one and two days.